Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrated BiopharmaINBP 36 5-Year Yield-on-Cost % is 0.00 as of Jul. 31, 2026. GuruFocus rates INBP with a GF Score™ of 36/100 and a GF Value™ of $0.26 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,168 Consumer Packaged Goods companies, Integrated Biopharma ranks worse than 85616.35% on this metric.
Integrated Biopharma's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Integrated Biopharma's 5-Year Yield-on-Cost % or its related term are showing as below:
INBP's 5-Year Yield-on-Cost % is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 3.405 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Integrated Biopharma 5-Year Yield-on-Cost % Related Terms
INBP vs HCWC, PAVS, BABB: 5-Year Yield-on-Cost % Comparison
For the Packaged Foods subindustry, Integrated Biopharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Biopharma 5-Year Yield-on-Cost % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Integrated Biopharma's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Integrated Biopharma (INBP) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 31, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Integrated Biopharma and its competitors. According to the industry distribution chart, Integrated Biopharma ranks #999999 out of 1168 companies in the Consumer Packaged Goods industry.
Is Integrated Biopharma's 5-Year Yield-on-Cost % too high?
Integrated Biopharma's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Integrated Biopharma ranks #999999 out of 1168 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Integrated Biopharma has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrated Biopharma's 5-Year Yield-on-Cost % compare to HCWC and PAVS?
According to the Consumer Packaged Goods industry distribution chart, Integrated Biopharma ranks #999999 out of 1168 companies for 5-Year Yield-on-Cost %. This places Integrated Biopharma in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 3.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Consumer Packaged Goods company?
The median 5-Year Yield-on-Cost % among Consumer Packaged Goods companies is 3.41, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Integrated Biopharma and its competitors. For the Consumer Packaged Goods industry, the median 5-Year Yield-on-Cost % is 3.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Biopharma's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Integrated Biopharma (INBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.26, compared to a current price of $0.16 — trading 38.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Integrated Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Integrated Biopharma (INBP), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Biopharma (INBP) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Biopharma stock appears to be undervalued.
The current stock price of $0.16 is trading 38.5% below its estimated GF Value™ of $0.26.
GuruFocus considers Integrated Biopharma to be Possible Value Trap.
Key valuation signals for INBP:
5-Year Yield-on-Cost %: 0.00
GF Value™: $0.26 vs. price of $0.16 (38.5% below fair value)
No single metric tells the full story. See the INBP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments: Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from the Contract Manufacturing segment, which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
36GF Score
Get the complete analysis for INBP
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBP has been successfully added to your 
